22.13
2.47 (12.56%)
| Previous Close | 19.66 |
| Open | 19.66 |
| Volume | 3,711,735 |
| Avg. Volume (3M) | 2,446,083 |
| Market Cap | 2,827,157,248 |
| Price / Sales | 3.57 |
| Price / Book | 2.95 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -25.14% |
| Operating Margin (TTM) | -31.33% |
| Diluted EPS (TTM) | -1.30 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Total Debt/Equity (MRQ) | 11.33% |
| Current Ratio (MRQ) | 5.37 |
| Operating Cash Flow (TTM) | 56.74 M |
| Levered Free Cash Flow (TTM) | 95.16 M |
| Return on Assets (TTM) | -12.43% |
| Return on Equity (TTM) | -22.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | 10x Genomics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -1.88 |
|
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China). |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Value |
| % Held by Insiders | 1.93% |
| % Held by Institutions | 101.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Stifel, 12.97%) | Buy |
| Median | 20.00 (-9.63%) | |
| Low | 19.00 (TD Cowen, -14.14%) | Hold |
| Average | 21.00 (-5.11%) | |
| Total | 1 Buy, 3 Hold | |
| Avg. Price @ Call | 20.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 02 Mar 2026 | 25.00 (12.97%) | Buy | 23.14 |
| 13 Feb 2026 | 20.00 (-9.62%) | Buy | 18.12 | |
| UBS | 20 Feb 2026 | 20.00 (-9.62%) | Hold | 18.88 |
| TD Cowen | 13 Feb 2026 | 19.00 (-14.14%) | Hold | 18.12 |
| 07 Jan 2026 | 18.00 (-18.66%) | Hold | 19.99 | |
| Leerink Partners | 27 Jan 2026 | 20.00 (-9.62%) | Hold | 21.62 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |